Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alexis McKee

Endocrinology, Diabetes & Metabolism Saint Louis, MO Medical Doctor

NPI 1144518069 CMS profile 623654

1 Barnes Jewish Hospital Plz, Div Im Endocrinology, Saint Louis, MO 63110

Open in the dashboard

General payments

$37,096

185 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alexis McKee of Saint Louis, MO is reported in the CMS Open Payments database as having received $37,096 across 185 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $149 1
2023 General $383 10
2022 General $9,637 18
2021 General $2,874 33
2020 General $21,859 59
2019 General $2,193 64

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alexis McKee
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Alexis McKee were reported at $149. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Alexis McKee Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $2,193 $494 $123–$2,253 $163
2020 $21,859 $335 $85–$1,841 $114
2021 $2,874 $398 $88–$1,981 $132
2022 $9,637 $364 $88–$1,568 $149
2023 $383 $420 $113–$1,614 $160
2024 $0 $440 $121–$1,646 $164
2025 $149 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $15,420 46 payments
  2. Novo Nordisk Inc $10,367 40 payments
  3. Medtronic, Inc. $3,777 3 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $3,170 46 payments
  5. Lilly USA, LLC $2,323 5 payments
  6. Medtronic MiniMed, Inc. $1,344 21 payments
  7. Radius Health, Inc. $152 2 payments
  8. Sequel Med Tech, LLC $149 1 payment
  9. Mannkind Corporation $73 4 payments
  10. Amgen Inc. $62 4 payments
  11. Other $258 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $14,575 18 payments
  2. Consulting Fee $9,255 5 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,460 8 payments
  4. Food and Beverage $4,359 130 payments
  5. Travel and Lodging $2,242 9 payments
  6. Education $204 15 payments
Products named General payments · program years 2019–2025
  1. FreeStyle Libre Pro $14,679 19 payments
  2. Tresiba $7,312 8 payments
  3. JARDIANCE Diabetes $3,144 43 payments
  4. RYBELSUS $2,381 10 payments
  5. JARDIANCE Diabetes $2,200 4 payments
  6. MINIMED 770G $1,917 2 payments
  7. Minimed 670G System $1,330 20 payments
  8. Ozempic $637 19 payments
  9. FreeStyle Libre 2 $312 8 payments
  10. Tymlos $152 2 payments
  11. Other $1,266 49 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

13

Median for Endocrinology: 1,959

Drug cost

$6,711

Median for Endocrinology: $890,201

Branded share of claims

100%

Median for Endocrinology: 57%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tradjenta Linagliptin Brand 13 $6,711

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$2,084

Medicare's payments for the services billed

Medicare patients

20

Average age 64

Services billed

26

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Chronic kidney disease 75%
Arthritis 55%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

185 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record